Efficacy of Gepotidacin Versus Nitrofurantoin for the Treatment of Lower Urinary Tract Infections
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 5th, 2025
|
Lower urinary tract infections are extremely common, with approximately half of all women worldwide reporting at least one episode during their lifetime. Although these infections are generally manageable with antibiotics, past misuse has contributed to the growing problem of antimicrobial resistance, highlighting the need for new treatment options. Gepotidacin is a novel therapeutic agent, and GlaxoSmithKline sponsored a study to compare its effectiveness to that of nitrofurantoin in treating urinary tract infections.
The phase 3 clinical trial enrolled 1,201 non-pregnant women with an average age of 50 years, all of whom had been diagnosed with a urinary tract infection within the preceding four days. About 40% of participants had a history of previous infections, and approximately one-third reported severe symptoms. Microbiological analysis revealed that Escherichia coli was the predominant uropathogen, accounting for 90% of cases, followed by Klebsiella pneumoniae at 3%.
Participants were randomly assigned to receive either 1500 mg of gepotidacin or 100 mg of nitrofurantoin, administered orally twice daily. Nitrofurantoin, one of the standard treatments for infections involving resistant organisms, functions by inhibiting bacterial enzymes necessary for DNA synthesis and metabolism. In contrast, gepotidacin acts by inhibiting the bacterial topoisomerase enzyme, preventing the relief of DNA supercoiling during replication and transcription.
Following five days of treatment, researchers found that the clinical success rates and microbiological clearance rates were approximately 50% for both nitrofurantoin and gepotidacin. This treatment success was consistent across the different types of uropathogens. Importantly, the study also noted that gepotidacin was effective in treating infections caused by uropathogens resistant to fluoroquinolones, trimethoprim-sulfamethoxazole, and other multidrug-resistant strains.
The phase 3 clinical trial enrolled 1,201 non-pregnant women with an average age of 50 years, all of whom had been diagnosed with a urinary tract infection within the preceding four days. About 40% of participants had a history of previous infections, and approximately one-third reported severe symptoms. Microbiological analysis revealed that Escherichia coli was the predominant uropathogen, accounting for 90% of cases, followed by Klebsiella pneumoniae at 3%.
Participants were randomly assigned to receive either 1500 mg of gepotidacin or 100 mg of nitrofurantoin, administered orally twice daily. Nitrofurantoin, one of the standard treatments for infections involving resistant organisms, functions by inhibiting bacterial enzymes necessary for DNA synthesis and metabolism. In contrast, gepotidacin acts by inhibiting the bacterial topoisomerase enzyme, preventing the relief of DNA supercoiling during replication and transcription.
Following five days of treatment, researchers found that the clinical success rates and microbiological clearance rates were approximately 50% for both nitrofurantoin and gepotidacin. This treatment success was consistent across the different types of uropathogens. Importantly, the study also noted that gepotidacin was effective in treating infections caused by uropathogens resistant to fluoroquinolones, trimethoprim-sulfamethoxazole, and other multidrug-resistant strains.